Certara, Inc. Common Stock
CERTCertara, Inc. is a global provider of modeling, simulation, and consulting services to the pharmaceutical, biotechnology, and regulatory communities. The company specializes in drug development, medical device development, and regulatory science, offering software and expertise to optimize clinical trials and accelerate the path to market for healthcare products.
Company News
The global in silico clinical trials market, valued at USD 1.84 billion in 2025, is projected to grow to USD 8.94 billion by 2035 at a 15.2% CAGR. Growth is driven by high failure rates in traditional clinical trials, regulatory acceptance of computational evidence, advances in AI and digital twins, and ethical concerns about animal testing. Nort...
Law firm Bragar Eagel & Squire is investigating Certara, Inc. for potential securities law violations following the company's Q1 2026 earnings announcement. Certara reported declining services revenue (down 4% YoY to $57.2M) and bookings (down 14% YoY to $66.6M), citing softer performance from major customers and exiting its regulatory business. ...
Law firm Johnson Fistel is investigating Certara, Inc. (NASDAQ: CERT) on behalf of investors who suffered losses following the company's May 2026 earnings report disclosing declining services revenue and bookings, along with execution challenges. The investigation was further prompted by the announcement of CFO John Gallagher's resignation effect...
The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform...
The Schall Law Firm announced an investigation into Certara, Inc. (NASDAQ: CERT) for potential securities law violations following the company's May 11, 2026 Q1 earnings report. Certara disclosed declining services revenues and bookings, attributing the weakness to softer performance from Tier 1 customers in MIDD services. The stock fell 19% on t...
